Recent Articles
Weekly Psychedelic Policy Briefing – August 9, 2026
In this week’s Psychedelic Policy Briefing, Investigative Journalist Jack Gorsline digs into the details of four major federal-level developments over the last 7 days. First up, the Department of Veterans Affairs launched a five-site psilocybin trial, and the drug it runs on belongs to a company preparing an application for approval. On capitol hill, the […]
By Jack Gorsline
The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science
By Josh Lipson, PhD and Roman Palitsky, MDiv, PhD
Filter
Weekly Psychedelic Policy Briefing – August 2, 2026
The House attached psychedelic amendments to the FY2027 defense bill, VA Secretary Doug Collins promoted…
By Jack Gorsline
Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month
Nine of twelve veterans with severe, treatment-resistant PTSD no longer met diagnostic criteria a month…
By Joe Moore
Psychedelic Policy Briefing: Week of July 27th, 2026
The House voted to extend the Pentagon’s psychedelic research program through 2033, then blocked a…
By Jack Gorsline
Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic Consciousness
Douglas Wingate, a Doctor of Traditional Chinese Medicine and licensed Oregon psilocybin facilitator, maps the…
By Douglas S. Wingate, DTCM, L.Ac.
Psychedelic Policy Briefing: Week of July 20th, 2026
This week in psychedelic policy: Texas moves ahead with state-funded ibogaine trials, Eli Lilly buys…
By Jack Gorsline
What Is Metaprogramming? A Practitioner’s Introduction
Ketamine-assisted therapist Rachel Turetzky explains metaprogramming: John Lilly’s term for consciously rewriting the beliefs that…